Drug and Therapeutics Bulletin

1 month ago | dtb.bmj.com | David Phizackerley |BMJ Journals

Drug-Related Side Effects and Adverse Reactions Health Care Quality, Access, and Evaluation In January 2025, an article published in The Lancet assessed the population-health impact of medicines that had been approved by the National Institute for Health and Care Excellence (NICE) between 2000 and 2020.1 Huseyin Naci and colleagues calculated a net health benefit from each new medicine and the estimated effect that theoretically could be obtained by using the money spent on those medicines...

2 months ago | dtb.bmj.com | Michael Wilcock |David Phizackerley |BMJ Journals

Drug-Related Side Effects and Adverse ReactionsHealth Care Quality, Access, and EvaluationThe importance of patient-centred care and the active engagement and involvement of patients in decisions about their own healthcare have long been recognised.1 For some treatment decisions, the best option may be obvious, but for many others, especially for preventative treatments, there can be several choices open to the patient.

Dec 4, 2024 | dtb.bmj.com | Joanna Owens |Teck K Khong

Adverse effects of antihypertensives in frail older people Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Sep 6, 2024 | dtb.bmj.com | David Phizackerley |BMJ Journals

Supporting the treatment of obesity Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Aug 17, 2024 | dtb.bmj.com | Michael Wilcock

Health Care Quality, Access, and EvaluationPrimary Health CareNHS England published guidance on 16 national medicines optimisation ‘opportunities’ for integrated care boards (ICBs) in 2023.1 These were selected to support ICBs in tackling inequalities, improving outcomes and value for money, and relate to appropriate use, access and uptake of medicines.2 ICBs are recommended to choose at least five of these opportunities alongside their local medicines optimisation priorities.